Table 1 Characteristics of patients before and after propensity score matching analysis
| Â | Unmanipulated data | Propensity score matching analysis | ||||
|---|---|---|---|---|---|---|
MSD | HID | P value | MSD | HID | P value | |
n (%) | 179 (16.9) | 881 (83.1) | Â | 155 (23.4) | 508 (76.6) | Â |
Patient sex | Â | Â | 0.005 | Â | Â | 0.12 |
 Male | 76 (42.5) | 476 (54.0) |  | 66 (42.6) | 253 (49.8) |  |
 Female | 103 (57.5) | 405 (46.0) |  | 89 (57.4) | 255 (50.2) |  |
Median months from diagnosis to HSCT | 6.3 (1.5–231.9) | 6.9 (1.6–187.5) | 0.009 | 6.1 (1.5–156.3) | 6.6 (1.5–184.8) | 0.03 |
Median age at HSCT (years) | 41 (11–58) | 39 (9–67) | 0.51 | 39 (11–58) | 36 (9–67) | 0.43 |
Age at HSCT (years) | Â | Â | 0.20 | Â | Â | 0.42 |
  < 40 | 82 (45.8) | 450 (51.1) |  | 81 (52.3) | 284 (55.9) |  |
  ≥ 40 | 97 (54.2) | 431 (48.9) |  | 74 (47.7) | 224 (44.1) |  |
Diagnosis | Â | Â | 0.58 | Â | Â | 0.81 |
 Acute myeloid leukemia | 83 (46.4) | 418 (47.4) |  | 71 (45.8) | 228 (44.9) |  |
 Myelodysplastic syndrome/ myeloproliferative neoplasm | 25 (14.0) | 95 (10.8) |  | 20 (12.9) | 58 (11.4) |  |
 Chronic myeloid leukemia | 8 (4.5) | 28 (3.2) |  | 7 (4.5) | 16 (3.1) |  |
 Acute lymphocytic leukemia | 63 (35.2) | 338 (38.4) |  | 57 (36.8) | 205 (40.4) |  |
 Plasma cell leukemia | 0 (0.0) | 2 (0.2) |  | 0 (0.0) | 1 (0.2) |  |
Lineage | Â | Â | 0.39 | Â | Â | 0.40 |
 Lymphoblastic malignancies | 63 (35.2) | 340 (38.6) |  | 57 (36.8) | 206 (406) |  |
 Myelogenous malignancies | 116 (64.8) | 541 (61.4) |  | 98 (63.2) | 302 (59.4) |  |
Refined disease risk index | Â | Â | 0.05 | Â | Â | 0.32 |
 Low | 19 (10.6) | 70 (7.9) |  | 17 (11.0) | 44 (8.7) |  |
 Intermediate | 134 (74.9) | 602 (68.3) |  | 113 (72.9) | 348 (68.5) |  |
 High | 21 (11.7) | 168 (19.1) |  | 20 (12.9) | 93 (18.3) |  |
 Very high | 5 (2.8) | 41 (4.7) |  | 5 (3.2) | 23 (4.5) |  |
Remission status | Â | Â | 0.01 | Â | Â | 0.34 |
 First complete remission, MRD negative | 125 (69.8) | 565 (64.1) |  | 94 (60.6) | 313 (61.6) |  |
 First complete remission, MRD positive | 32 (17.9) | 115(13.1) |  | 39 (25.2) | 99 (19.5) |  |
 Second or third complete remission | 11 (6.1) | 100 (11.4) |  | 11 (7.1) | 47 (9.3) |  |
 Active disease | 11 (6.1) | 101 (11.5) |  | 11 (7.1) | 49 (9.6) |  |
Body mass index at HSCT (kg/m2) | Â | Â | 0.13 | Â | Â | 0.10 |
 < 18.5 | 12 (6.7) | 92 (10.4) |  | 11 (7.1) | 60 (11.8) |  |
 ≥ 18.5 | 167 (93.3) | 789 (89.6) |  | 144 (92.9) | 448 (88.2) |  |
Conditioning regimen | Â | Â | 0.16 | Â | Â | 0.14 |
 Myeloablative | 167 (93.3) | 792 (89.9) |  | 146 (94.2) | 459 (90.4) |  |
 Reduced intensity | 12 (6.7) | 89 (10.1) |  | 9 (5.8) | 49 (9.6) |  |
Donor sex | Â | Â | 0.007 | Â | Â | 0.65 |
 Male | 94 (52.5) | 557 (63.2) |  | 85 (54.8) | 289 (56.9) |  |
 Female | 85 (47.5) | 324 (36.8) |  | 70 (45.2) | 219 (43.1) |  |
Median donor age (years) | 40 (10–61) | 32 (8–64) |  < 0.001 | 38 (10–57) | 34 (9–64) | 0.04 |
Donor age (years) |  |  |  < 0.001 |  |  | 0.26 |
  < 40 | 88 (49.2) | 594 (67.4) |  | 88 (56.8) | 314 (61.8) |  |
  ≥ 40 | 91 (50.8) | 287 (32.6) |  | 67 (43.2) | 194 (38.2) |  |
Donor-recipient sex | Â | Â | 0.002 | Â | Â | 0.35 |
 Female to female | 47 (26.3) | 160 (18.2) |  | 42 (27.1) | 126 (24.8) |  |
 Male to male | 38 (21.2) | 165 (18.7) |  | 38 (24.5) | 160 (31.5) |  |
 Female to male | 38 (21.2) | 311 (35.3) |  | 28 (18.1) | 93 (18.3) |  |
 Male to female | 56 (31.3) | 245 (27.8) |  | 47 (30.3) | 129 (25.4) |  |
ABO match, no. (%) | Â | Â | 0.60 | Â | Â | 0.58 |
 Matched | 95 (53.1) | 468 (53.1) |  | 81 (52.3) | 257 (50.6) |  |
 Major mismatched | 34 (19.0) | 200 (22.7) |  | 29 (18.7) | 121 (23.8) |  |
 Minor mismatched | 40 (22.3) | 166 (18.8) |  | 35 (22.6) | 102 (20.1) |  |
 Bidirectional mismatch | 10 (5.6) | 47 (5.3) |  | 10 (6.5) | 28 (5.5) |  |
 Median follow-up (days) | 23.3 (0.3–67.4) | 20.3 (0.1–115.8) | 0.43 | 22.6 (0.3–66.4) | 20.9 (0.1–77.0) | 0.63 |